Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Stintzing

Showing results (91-100 of 206) with videos related to

Pageof 21
Sort By:
Acta Haematologica|May 5, 2025
Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trialPhilipp le Coutre, Andreas Burchert, Susanne Saußele, et al.
Anti-Cancer Drugs|March 24, 2012
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysisDominik Paul Modest, Anke Reinacher-Schick, Sebastian Stintzing, et al.
Future Oncology (London, England)|July 11, 2015
KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancerPeter Camaj, Stefano Primo, Yan Wang, et al.
European Journal of Radiology|March 3, 2018
Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trialFelix O Hofmann, Julian W Holch, Volker Heinemann, et al.
Journal of Clinical Medicine|August 26, 2022
Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I InvestigationJana K Striefler, Jens M Stieler, Christopher C M Neumann, et al.
Anti-Cancer Drugs|November 9, 2013
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment)Dominik P Modest, Christoph Schulz, Ludwig F von Weikersthal, et al.
Oncology|September 6, 2012
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trialsDominik P Modest, Thomas Brodowicz, Sebastian Stintzing, et al.
Anti-Cancer Drugs|July 29, 2011
Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS statusDominik P Modest, Sebastian Stintzing, Ruediger P Laubender, et al.
Clinical Colorectal Cancer|September 12, 2020
Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306Matthias F Froelich, Elina L Petersen, Volker Heinemann, et al.
Langenbeck'S Archives of Surgery|January 15, 2013
Combined resection of colorectal hepatic-pulmonary metastases shows improved outcome over chemotherapy aloneGeorgios Meimarakis, Martin Angele, Claudius Conrad, et al.
Pageof 21

Showing results (91-100 of 206) with videos related to

Sort By:
Pageof 21
Acta Haematologica|May 5, 2025
Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trialPhilipp le Coutre, Andreas Burchert, Susanne Saußele, et al.
Anti-Cancer Drugs|March 24, 2012
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysisDominik Paul Modest, Anke Reinacher-Schick, Sebastian Stintzing, et al.
Future Oncology (London, England)|July 11, 2015
KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancerPeter Camaj, Stefano Primo, Yan Wang, et al.
European Journal of Radiology|March 3, 2018
Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trialFelix O Hofmann, Julian W Holch, Volker Heinemann, et al.
Journal of Clinical Medicine|August 26, 2022
Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I InvestigationJana K Striefler, Jens M Stieler, Christopher C M Neumann, et al.
Anti-Cancer Drugs|November 9, 2013
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment)Dominik P Modest, Christoph Schulz, Ludwig F von Weikersthal, et al.
Oncology|September 6, 2012
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trialsDominik P Modest, Thomas Brodowicz, Sebastian Stintzing, et al.
Anti-Cancer Drugs|July 29, 2011
Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS statusDominik P Modest, Sebastian Stintzing, Ruediger P Laubender, et al.
Clinical Colorectal Cancer|September 12, 2020
Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306Matthias F Froelich, Elina L Petersen, Volker Heinemann, et al.
Langenbeck'S Archives of Surgery|January 15, 2013
Combined resection of colorectal hepatic-pulmonary metastases shows improved outcome over chemotherapy aloneGeorgios Meimarakis, Martin Angele, Claudius Conrad, et al.
Pageof 21